Anastrozole

Overview

Anastrozole is a third-generation non-steroidal aromatase inhibitor FDA-approved for breast cancer treatment. In the hormonal health community it is widely used off-label to control estrogen levels in men undergoing testosterone replacement therapy or using anabolic compounds that aromatize to estrogen. By inhibiting the enzyme responsible for converting androgens to estrogens, anastrozole allows for management of estrogen-related side effects while maintaining the benefits of androgen optimization. It has a well-established clinical profile from its breast cancer applications and extensive off-label use data.

Where does Anastrozole sit?

See how this peptide compares across all 70 peptides in our database.

Mechanism of Action

Anastrozole competitively and selectively inhibits aromatase (CYP19A1), the enzyme complex responsible for the biosynthesis of estrogens from androgens. It blocks the conversion of testosterone to estradiol and androstenedione to estrone in peripheral tissues — primarily adipose tissue, liver, and muscle. By reducing circulating estradiol levels, anastrozole mitigates estrogen-dependent side effects including gynecomastia, water retention, and mood changes associated with elevated estrogen. In post-menopausal breast cancer, it starves estrogen-receptor-positive tumors of their growth signal. In TRT contexts it is used at much lower doses than in oncology to maintain estrogen in physiological range rather than suppress it completely — as some estrogen is essential for cardiovascular health, bone density, and libido in men.

Dosage Information

Typical Dose

0.25-0.5 mg, 2-3 times weekly (TRT adjunct)

Frequency

2-3 times weekly

Administration

Oral tablet

Notes

Requires regular estradiol monitoring to avoid over-suppression. Estrogen should be managed into range, not eliminated. Over-suppression causes joint pain, low libido, mood depression, and bone loss.

Potential Side Effects

Joint pain and stiffness (common at oncology doses, less so at TRT doses)Hot flashes (common at oncology doses)Bone density loss with long-term use (uncommon at low TRT doses)Mood changes (uncommon)Elevated cholesterol (uncommon)

Community Experiences

No experiences shared yet. Be the first!

Quick Facts

Administration: Oral tablet
Typical Dose: 0.25-0.5 mg, 2-3 times weekly (TRT adjunct)
Frequency: 2-3 times weekly
References: 0 curated + 0 from PubMed